Pharma BD Deal Intelligence

Jazz Pharmaceuticals plc / Gentium S.p.A.

2013 · Acquisition/Merger · $1.0B · Complete

Announcement Sentiment

Strongly positive

Jazz to acquire Gentium at $57.00/share cash tender (~$1B); added EU-approved Defitelio for severe hepatic VOD to hematology/oncology orphan portfolio.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Dec 19, 2013
Closed Feb 21, 2014
Deal value $1.0B
Deal type Acquisition/Merger
Therapeutic area Severe hepatic veno-occlusive disease (VOD) post-HSCT
Indications Severe hepatic veno-occlusive disease (VOD) post-HSCT
Key assets Defitelio (defibrotide)
Mechanism Polydeoxyribonucleotide (anti-thrombotic, profibrinolytic, anti-inflammatory)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals